Healthcare of Ontario Pension Plan Trust Fund Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Healthcare of Ontario Pension Plan Trust Fund trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 34.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 75,462 shares of the biopharmaceutical company’s stock after selling 39,251 shares during the period. Healthcare of Ontario Pension Plan Trust Fund’s holdings in Regeneron Pharmaceuticals were worth $58,305,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC boosted its position in Regeneron Pharmaceuticals by 635.5% during the first quarter. Renaissance Technologies LLC now owns 66,802 shares of the biopharmaceutical company’s stock worth $51,614,000 after purchasing an additional 57,720 shares in the last quarter. Gabelli Funds LLC increased its position in shares of Regeneron Pharmaceuticals by 19.5% in the first quarter. Gabelli Funds LLC now owns 2,197 shares of the biopharmaceutical company’s stock valued at $1,697,000 after buying an additional 358 shares in the last quarter. GC Wealth Management RIA LLC increased its position in shares of Regeneron Pharmaceuticals by 510.9% in the first quarter. GC Wealth Management RIA LLC now owns 2,297 shares of the biopharmaceutical company’s stock valued at $1,775,000 after buying an additional 1,921 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in shares of Regeneron Pharmaceuticals by 6.6% during the 1st quarter. Public Employees Retirement System of Ohio now owns 43,886 shares of the biopharmaceutical company’s stock worth $33,908,000 after buying an additional 2,710 shares during the last quarter. Finally, Compound Planning Inc. raised its stake in shares of Regeneron Pharmaceuticals by 8.1% during the 1st quarter. Compound Planning Inc. now owns 1,811 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a report on Monday, May 18th. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $787.88.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

Regeneron Pharmaceuticals Stock Up 0.6%

REGN opened at $656.01 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The firm has a market cap of $69.35 billion, a P/E ratio of 15.98, a PEG ratio of 1.45 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The business’s fifty day simple moving average is $635.78 and its 200 day simple moving average is $714.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same period in the prior year, the firm earned $8.22 EPS. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is currently 9.16%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.